疫苗接种时代和加强针接种后的严重急性呼吸综合征冠状病毒2型血清学

IF 1.6 Q4 INFECTIOUS DISEASES
Latha Dulipsingh , Maxine Lang , Margaret R. Diffenderfer , Lisa Cook , Jennifer Puff , Lynn Diaz , Lihong He , Ernst J. Schaefer
{"title":"疫苗接种时代和加强针接种后的严重急性呼吸综合征冠状病毒2型血清学","authors":"Latha Dulipsingh ,&nbsp;Maxine Lang ,&nbsp;Margaret R. Diffenderfer ,&nbsp;Lisa Cook ,&nbsp;Jennifer Puff ,&nbsp;Lynn Diaz ,&nbsp;Lihong He ,&nbsp;Ernst J. Schaefer","doi":"10.1016/j.jcvp.2022.100130","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects.</p></div><div><h3>Methods</h3><p>Utilizing assays for serum SARS-CoV-2 spike (S) protein antibody (Roche) and neutralizing antibody (Diazyme), both &gt;90% IgG, we measured antibodies in 13,189 subjects in the post-vaccination era, and in 69 subjects before and 60 days after booster vaccination.</p></div><div><h3>Results</h3><p>In 2021, in 10,267 subjects, 25·0% had negative S protein levels (&lt;0.80 U/L), 24·4% had low positive levels (0.80-250 U/L), and 50·7% had high positive levels (&gt;250 U/L). Median neutralizing antibody levels were 1·16 and 2·06 AU/mL in the low and high positive groups, respectively. In 2022, we evaluated 2,016 subjects where samples were diluted 1:100 if S protein antibody levels were &gt;250 U/L. Median S protein and neutralizing antibody levels were 2,065 U/L (86.3% positivity) and 2·68 AU/mL (68.0% positivity), respectively. Antibody levels were also measured in 69 subjects before and 60 days after receiving SARS-CoV-2 booster vaccinations. Treatment resulted in a 15-fold increase in S protein antibody levels from 1,010 to 17,236 U/L, and a 6-fold increase in neutralizing antibody from 1·51 to 12·51 AU/mL in neutralizing antibody levels, respectively (both <em>P</em>&lt;0.00001), with a wide variability in response.</p></div><div><h3>Conclusions</h3><p>Our data indicate that by early 2022 86% of subjects had positive SARS-CoV-2 S protein antibody levels, and that these levels and neutralizing antibody levels were increased 15-fold and 6-fold, respectively, 60 days after SARS-Cov-2 booster vaccination.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 1","pages":"Article 100130"},"PeriodicalIF":1.6000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759815/pdf/","citationCount":"1","resultStr":"{\"title\":\"Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination\",\"authors\":\"Latha Dulipsingh ,&nbsp;Maxine Lang ,&nbsp;Margaret R. Diffenderfer ,&nbsp;Lisa Cook ,&nbsp;Jennifer Puff ,&nbsp;Lynn Diaz ,&nbsp;Lihong He ,&nbsp;Ernst J. Schaefer\",\"doi\":\"10.1016/j.jcvp.2022.100130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects.</p></div><div><h3>Methods</h3><p>Utilizing assays for serum SARS-CoV-2 spike (S) protein antibody (Roche) and neutralizing antibody (Diazyme), both &gt;90% IgG, we measured antibodies in 13,189 subjects in the post-vaccination era, and in 69 subjects before and 60 days after booster vaccination.</p></div><div><h3>Results</h3><p>In 2021, in 10,267 subjects, 25·0% had negative S protein levels (&lt;0.80 U/L), 24·4% had low positive levels (0.80-250 U/L), and 50·7% had high positive levels (&gt;250 U/L). Median neutralizing antibody levels were 1·16 and 2·06 AU/mL in the low and high positive groups, respectively. In 2022, we evaluated 2,016 subjects where samples were diluted 1:100 if S protein antibody levels were &gt;250 U/L. Median S protein and neutralizing antibody levels were 2,065 U/L (86.3% positivity) and 2·68 AU/mL (68.0% positivity), respectively. Antibody levels were also measured in 69 subjects before and 60 days after receiving SARS-CoV-2 booster vaccinations. Treatment resulted in a 15-fold increase in S protein antibody levels from 1,010 to 17,236 U/L, and a 6-fold increase in neutralizing antibody from 1·51 to 12·51 AU/mL in neutralizing antibody levels, respectively (both <em>P</em>&lt;0.00001), with a wide variability in response.</p></div><div><h3>Conclusions</h3><p>Our data indicate that by early 2022 86% of subjects had positive SARS-CoV-2 S protein antibody levels, and that these levels and neutralizing antibody levels were increased 15-fold and 6-fold, respectively, 60 days after SARS-Cov-2 booster vaccination.</p></div>\",\"PeriodicalId\":73673,\"journal\":{\"name\":\"Journal of clinical virology plus\",\"volume\":\"3 1\",\"pages\":\"Article 100130\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759815/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical virology plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667038022000692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038022000692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 1

摘要

背景严重急性呼吸系统综合征冠状病毒2型疫情已在全球造成600多万人死亡。在疫苗接种前的时代,我们注意到81624名受试者的严重急性呼吸系统综合征冠状病毒2型IgG抗体阳性率为5.3%。方法利用血清严重急性呼吸系统综合征冠状病毒2型刺突蛋白抗体(Roche)和中和抗体(Diazyme)的测定,两者均>;90%的IgG,我们在接种疫苗后的13189名受试者中,以及在加强针接种前和接种后60天的69名受试人中测量了抗体。结果2021年,在10267名受试者中,25.0%的受试者S蛋白水平为阴性(<;0.80 U/L),24.4%的受试人S蛋白水平低(0.80-250 U/L)和50.7%的受试人员S蛋白水平高(>;250 U/L)。低阳性组和高阳性组的中位中和抗体水平分别为1.16和2.06AU/mL。2022年,我们评估了2016名受试者,如果S蛋白抗体水平>;250 U/L。中位S蛋白和中和抗体水平分别为2065U/L(阳性率86.3%)和2.68AU/mL(阳性度68.0%)。69名受试者在接种严重急性呼吸系统综合征冠状病毒2型加强疫苗前和接种后60天也测量了抗体水平。治疗导致S蛋白抗体水平从1010增加到17236 U/L,增加了15倍,中和抗体水平从1.51增加到12.51 AU/mL,分别增加了6倍(均P<;0.00001),反应变化很大。结论我们的数据表明,到2022年初,86%的受试者的严重急性呼吸系统综合征冠状病毒2型S蛋白抗体水平呈阳性,在接种严重急性呼吸系综合征冠状病毒二型加强针60天后,这些水平和中和抗体水平分别增加了15倍和6倍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination

Background

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects.

Methods

Utilizing assays for serum SARS-CoV-2 spike (S) protein antibody (Roche) and neutralizing antibody (Diazyme), both >90% IgG, we measured antibodies in 13,189 subjects in the post-vaccination era, and in 69 subjects before and 60 days after booster vaccination.

Results

In 2021, in 10,267 subjects, 25·0% had negative S protein levels (<0.80 U/L), 24·4% had low positive levels (0.80-250 U/L), and 50·7% had high positive levels (>250 U/L). Median neutralizing antibody levels were 1·16 and 2·06 AU/mL in the low and high positive groups, respectively. In 2022, we evaluated 2,016 subjects where samples were diluted 1:100 if S protein antibody levels were >250 U/L. Median S protein and neutralizing antibody levels were 2,065 U/L (86.3% positivity) and 2·68 AU/mL (68.0% positivity), respectively. Antibody levels were also measured in 69 subjects before and 60 days after receiving SARS-CoV-2 booster vaccinations. Treatment resulted in a 15-fold increase in S protein antibody levels from 1,010 to 17,236 U/L, and a 6-fold increase in neutralizing antibody from 1·51 to 12·51 AU/mL in neutralizing antibody levels, respectively (both P<0.00001), with a wide variability in response.

Conclusions

Our data indicate that by early 2022 86% of subjects had positive SARS-CoV-2 S protein antibody levels, and that these levels and neutralizing antibody levels were increased 15-fold and 6-fold, respectively, 60 days after SARS-Cov-2 booster vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of clinical virology plus
Journal of clinical virology plus Infectious Diseases
CiteScore
2.20
自引率
0.00%
发文量
0
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信